An efficient and safe MUC1-dendritic cell-derived exosome conjugate vaccine elicits potent cellular and humoral immunity and tumor inhibition in vivo

Blattman, 2004, Cancer immunotherapy: a treatment for the masses, Science, 305, 200, 10.1126/science.1100369 Fang, 2018, Generation of a graft versus anticancer immune response through skin allograft with tumor, J. Biomed. Nanotechnol., 14, 575, 10.1166/jbn.2018.2560 Zhang, 2016, One-shot immunomodulatory nanodiamond agents for cancer immunotherapy, Adv. Mater., 28, 2699, 10.1002/adma.201506232 Cai, 2014, Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells, Angew. Chem. Int. Ed. Engl., 53, 1699, 10.1002/anie.201308875 Gao, 2014, Covalent bond or noncovalent bond: a supramolecular strategy for the construction of chemically synthesized vaccines, Chemistry, 20, 13541, 10.1002/chem.201404013 Pan, 2018, Antigen-directed fabrication of a multifunctional nanovaccine with ultrahigh antigenloading efficiency for tumor photothermal-immunotherapy, Adv. Mater., 30, 10.1002/adma.201704408 Melero, 2014, Therapeutic vaccines for cancer: an overview of clinical trials, Nat. Rev. Clin. Oncol., 11, 509, 10.1038/nrclinonc.2014.111 Bachmann, 2010, Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns, Nat. Rev. Immunol., 10, 787, 10.1038/nri2868 Marrack, 2009, Towards an understanding of the adjuvant action of aluminium, Nat. Rev. Immunol., 9, 287, 10.1038/nri2510 Wendorf, 2006, A practical approach to the use of nanoparticles for vaccine delivery, J. Pharm. Sci., 95, 2738, 10.1002/jps.20728 Liu, 2018, Aluminum hydroxide colloid vaccine encapsulated in yeast shells with enhanced humoral and cellular immune responses, Biomaterials, 167, 32, 10.1016/j.biomaterials.2018.03.014 Ishii, 2007, Toll or toll-free adjuvant path toward the optimal vaccine development, J. Clin. Immunol., 27, 363, 10.1007/s10875-007-9087-x Kalani, 2014, Curcumin-primed exosomes mitigate endothelial cell dysfunction during hyperhomocysteinemia, Life Sci., 107, 1, 10.1016/j.lfs.2014.04.018 Pitt, 2014, Dendritic cell-derived exosomes as immunotherapies in the fight against cancer, J. Immunol., 193, 1006, 10.4049/jimmunol.1400703 Bol, 2016, Dendritic cell-based immunotherapy: state of the art and beyond, Clin. Cancer Res., 22, 1897, 10.1158/1078-0432.CCR-15-1399 Mignot, 2006, Prospects for exosomes in immunotherapy of cancer, J. Cell. Mol. Med., 10, 376, 10.1111/j.1582-4934.2006.tb00406.x Pitt, 2016, Dendritic cell-derived exosomes for cancer therapy, J. Clin. Invest., 126, 1224, 10.1172/JCI81137 Robbins, 2014, Regulation of immune responses by extracellular vesicles, Nat. Rev. Immunol., 14, 195, 10.1038/nri3622 Fu, 2020, DC-based vaccines for cancer immunotherapy, Vaccines, 8, 706, 10.3390/vaccines8040706 Kanchanapally, 2019, Drug-loaded exosomal preparations from different cell types exhibit distinctive loading capability, yield, and antitumor efficacies: a comparative analysis, Int. J. Nanomed., 14, 531, 10.2147/IJN.S191313 Chaput, 2004, Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection, J. Immunol., 172, 2137, 10.4049/jimmunol.172.4.2137 Bobisse, 2016, Neoantigen-based cancer immunotherapy, Ann. Transl. Med., 4, 262, 10.21037/atm.2016.06.17 Näslund, 2013, Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity, J. Immunol., 190, 2712, 10.4049/jimmunol.1203082 Johnsen, 2014, A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy, Biochim. Biophys. Acta, 1846, 75 Chen, 2014, Epigenetic regulation of connective tissue growth factor by MicroRNA-214 delivery in exosomes from mouse or human hepatic stellate cells, Hepatology, 59, 1118, 10.1002/hep.26768 Haney, 2015, Exosomes as drug delivery vehicles for Parkinson's disease therapy, J. Control. Release, 207, 18, 10.1016/j.jconrel.2015.03.033 Petros, 2010, Strategies in the design of nanoparticles for therapeutic applications, Nat. Rev. Drug Discov., 9, 615, 10.1038/nrd2591 Riehemann, 2009, Nanomedicine-challenge and perspectives, Angew. Chem. Int. Ed., 48, 872, 10.1002/anie.200802585 Salazar-González, 2015, Gold nanoparticles and vaccine development, Expert Rev. Vaccines, 14, 1197, 10.1586/14760584.2015.1064772 Gehrmann, 2013, Synergistic induction of adaptive antitumor immunity by codelivery of antigen with alpha-galactosylceramide on exosomes, Cancer Res., 73, 3865, 10.1158/0008-5472.CAN-12-3918 Viaud, 2010, Dendritic cell-derived exosomes for cancer immunotherapy: what's next?, Cancer Res, 70, 1281, 10.1158/0008-5472.CAN-09-3276 Liu, 2019, Design strategies and application progress of therapeutic exosomes, Theranostics, 9, 1015, 10.7150/thno.30853 Hollingsworth, 2004, Mucins in cancer: protection and control of the cell surface, Nat. Rev. Cancer, 4, 45, 10.1038/nrc1251 Kufe, 2009, Mucins in cancer: function, prognosis and therapy, Nat. Rev. Cancer, 9, 874, 10.1038/nrc2761 Senapati, 2010, Mucin-interacting proteins: from function to therapeutics, Trends Biochem. Sci., 35, 236, 10.1016/j.tibs.2009.10.003 Yin, 2018, Antitumor humoral and T Cell responses by Mucin-1 conjugates of bacteriophage Q-beta in wild-type mice, ACS Chem. Biol., 13, 1668, 10.1021/acschembio.8b00313 Xiao, 2016, Synthesis and immunological evaluation of MUC1 glycopeptide conjugates bearing N-acetyl modified STn derivatives as anticancer vaccines, Org. Biomol. Chem., 14, 7226, 10.1039/C6OB01092J Liu, 2020, Synthetic MUC1 breast cancer vaccine containing a Toll-like receptor 7 agonist exerts antitumor effects, Oncol. Lett., 20, 2369, 10.3892/ol.2020.11762 Liu, 2018, Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer, Mol. Ther., 26, 45, 10.1016/j.ymthe.2017.10.020 Liu, 2020, Design, synthesis, and preliminary immunological studies of MUC1-based antitumor vaccines adjuvanted with R- and S-FSL-1, ACS Med. Chem. Lett., 11, 1371, 10.1021/acsmedchemlett.9b00579 Théry, 2006, Isolation and characterization of exosomes from cell culture supernatants and biological fluids, Curr. Protoc. Cell Biol., 3, 322 van den Boorn, 2011, SiRNA delivery with exosome nanoparticles, Nat. Biotechnol., 29, 325, 10.1038/nbt.1830 Tan, 2013, Exosomes as nano-theranostic delivery platforms for gene therapy, Adv. Drug Deliv. Rev., 65, 357, 10.1016/j.addr.2012.06.014 Cai, 2019, Heterologous prime-boost enhances the antitumor immune response elicited by plant-virus-based cancer vaccine, J. Am. Chem. Soc., 141, 6509, 10.1021/jacs.9b01523 Wu, 2018, Protective epitope discovery and design of MUC1-based vaccine for effective tumor protections in immunotolerant mice, J. Am. Chem. Soc., 140, 16596, 10.1021/jacs.8b08473 Lawrence, 2020, How neutrophils meet their end, Trends Immunol., 41, 531, 10.1016/j.it.2020.03.008 Kolaczkowska, 2013, Neutrophil recruitment and function in health and inflammation, Nat. Rev. Immunol., 13, 159, 10.1038/nri3399 Bobisse, 2016, Neoantigen-based cancer immunotherapy, Ann. Transl. Med., 4, 262, 10.21037/atm.2016.06.17 Näslund, 2013, Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity, J. Immunol., 190, 2712, 10.4049/jimmunol.1203082 Liu, 2013, Nanoparticles-based multi-adjuvant whole cell tumor vaccine for cancer immunotherapy, Biomaterials, 34, 8291, 10.1016/j.biomaterials.2013.07.020 Joffre, 2012, Cross-presentation by dendritic cells, Nat. Rev. Immunol., 12, 557, 10.1038/nri3254 Li, 2011, Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response, Nat Nanotechnol, 6, 645, 10.1038/nnano.2011.153 Joshi, 2012, Targeting tumor antigens to dendritic cells using particulate carriers, J. Control. Release, 161, 25, 10.1016/j.jconrel.2012.05.010 Compañón, 2019, Structure-based design of potent tumor-associated antigens: modulation of peptide presentation by single-atom O/S or O/Se substitutions at the glycosidic linkage, J. Am. Chem. Soc., 141, 4063, 10.1021/jacs.8b13503 Wong, 2016, Advances in therapeutic cancer vaccines, Adv. Immunol., 130, 191, 10.1016/bs.ai.2015.12.001 Chaput, 2006, Dendritic cell derived-exosomes: biology and clinical implementations, J. Leukoc. Biol., 80, 471, 10.1189/jlb.0206094 Qazi, 2009, Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism, Blood, 113, 2673, 10.1182/blood-2008-04-153536 Andre, 2002, Malignant effusions and immunogenic tumour-derived exosomes, Lancet, 360, 295, 10.1016/S0140-6736(02)09552-1 André, 2004, Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells, J. Immunol., 172, 2126, 10.4049/jimmunol.172.4.2126 Yao, 2013, Tumor cell-derived exosome-targeted dendritic cells stimulate stronger CD8+ CTL responses and antitumor immunities, Biochem. Biophys. Res. Commun., 436, 60, 10.1016/j.bbrc.2013.05.058 Tkach, 2017, Qualitative differences in T-cell activation by dendritic cell-derived extracellular vesicle subtypes, EMBO J., 36, 3012, 10.15252/embj.201696003 Wolfert, 2013, Adaptive immune activation: glycosylation does matter, Nat. Chem. Biol., 9, 776, 10.1038/nchembio.1403 Taylor-Papadimitriou, 2018, Latest developments in MUC1 immunotherapy, Biochem. Soc. Trans., 46, 659, 10.1042/BST20170400 Tang, 2019, Employing macrophage-derived microvesicle for kidney-targeted delivery of dexamethasone: an efficient therapeutic strategy against renal inflammation and fibrosis, Theranostics, 9, 4740, 10.7150/thno.33520 Li, 2020, Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer, Acta Biomater., 101, 519, 10.1016/j.actbio.2019.10.022 Ha, 2016, Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges, Acta Pharmacol. Sin. B, 6, 287, 10.1016/j.apsb.2016.02.001 Rufino-Ramos, 2017, Extracellular vesicles: novel promising delivery systems for therapy of brain diseases, J. Control. Release, 262, 247, 10.1016/j.jconrel.2017.07.001 Saari, 2015, Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells, J. Control. Release, 220, 727, 10.1016/j.jconrel.2015.09.031 Liu, 2017, Potentiating the immune response of MUC1-based antitumor vaccines using a peptide-based nanovector as a promising vaccine adjuvant, Chem. Commun., 53, 9486, 10.1039/C7CC04386D Colino, 2006, Exosomes from bone marrow dendritic cells pulsed with diphtheria toxoid preferentially induce type 1 antigen-specific IgG responses in naive recipients in the absence of free antigen, J. Immunol., 177, 3757, 10.4049/jimmunol.177.6.3757 Wolfert, 2013, Adaptive immune activation: glycosylation does matter, Nat. Chem. Biol., 9, 776, 10.1038/nchembio.1403 Rudra, 2010, A self-assembling peptide acting as an immune adjuvant, Proc. Natl. Acad. Sci. U. S. A., 107, 622, 10.1073/pnas.0912124107